Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 10/2010

01-10-2010 | Original Article

Survivin Expression in Colorectal Carcinomas: Correlations with Clinicopathological Parameters and Survival

Authors: J. G. Kalliakmanis, Ch. Kouvidou, C. Latoufis, G. Kouvatseas, D. Anagnostakis, G. Papatheodoridis, J. Koskinas, A. Archimandritis

Published in: Digestive Diseases and Sciences | Issue 10/2010

Login to get access

Abstract

Background

Survivin is a new member of the Inhibitor of apoptosis protein family that has a dual function as a mitotic regulator and apoptosis inhibitor. Survivin is prominently expressed in transformed cell lines and in many human cancers, including colorectal carcinoma. The aim of this study is to investigate the expression of survivin in colorectal carcinomas and its possible associations with clinicopathological parameters and patient survival.

Materials and Methods

Sections of formalin-fixed paraffin-embedded tissues from 77 colorectal carcinomas were immunohistochemistry stained for survivin.

Results

Survivin was mainly detected in the bottom of the glands of normal mucosa with mainly cytoplasmic localization. No survivin expression was found in infiltrating lymphocytes, fibroblasts, smooth muscle cells or neural tissue. Survivin staining was detected in 68/77 (88.3%) colorectal carcinomas. Survivin expression was found to be significantly associated with tumor differentiation (P = 0.02) but not with gender, age or Dukes stage. Survival did not differ according to survivin expression.

Conclusion

Survivin was found in the majority of colorectal carcinomas, suggesting that its expression is an early event in colorectal carcinogenesis. Its expression is statistically significantly associated with tumor differentiation but not with patient survival.
Literature
1.
Ponnelle T, Chapusot C, Martin L, et al. Cellular localization of Survivin: impact on the prognosis in colorectal cancer. J Cancer Res Clin Oncol. 2005;131:504–510.CrossRefPubMed
2.
Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917–921.CrossRefPubMed
3.
Mahotka C, Wendel M, Springer E, et al. Survivin-Δex3 and survivin 2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 1999;59:6097–6102.PubMed
4.
Badran A, Yoshida A, Ishikawa K, et al. Identification of a novel splice variant of the human anti-apoptosis gene survivin. Biochem Biophys Res Commun. 2004;314:902–907.CrossRefPubMed
5.
Gazouli M, Tzanakis N, Rallis G, et al. Survivin -31G/C promoter polymorphism and sporadic colorectal cancer. Int J Colorectal Dis. 2009;24:145–150.CrossRefPubMed
6.
Shin S, Sung BJ, Cho YS, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry. 2001;40:1117–1123.CrossRefPubMed
7.
Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998;58:5315–5320.PubMed
8.
Salvensen GS, Dixit VM. Caspases: intracellular signaling by proteases. Cell. 1997;91:443–446.CrossRef
9.
O’ Connor DS, Grossman D, Plescia J, et al. Regulation of apoptosis at cell division by p34 cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA. 2000;97:13103–13107.CrossRef
10.
Fortugno P, Wall NR, Giodini A, et al. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci. 2002;115:575–585.PubMed
11.
Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396:580–584.CrossRefPubMed
12.
O’Driscoll L, Linehan R, Clynes M. Survivin: role in normal cells and in pathological conditions. Curr Cancer Drug Targets. 2003;3:131–152.CrossRefPubMed
13.
Adida C, Crotty PL, McGrath J, et al. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol. 1998;152:43–49.PubMed
14.
Kato J, Kuwabara Y, Mitani M, et al. Expression of survivin in oesophageal cancer: correlation with the prognosis and response to chemotheraphy. Int J Cancer. 2001;95:92–95.CrossRefPubMed
15.
Ikeguchi M, Kaibara N. Survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma. Br J Cancer. 2001;87(8):883–887.CrossRef
16.
Lu CD, Altieri DC, Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 1998;58:1808–1812.PubMed
17.
Sarela AI, Macadam RC, Farmery SM, et al. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut. 2000;46:645–650.CrossRefPubMed
18.
Swana HS, Grossman D, Antony JN, et al. Tumour content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med. 1999;341:452–453.CrossRefPubMed
19.
Monzo M, Rosell R, Felip E, et al. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as aprognostic marker in non-small-cell lung cancers. J Clin Oncol. 1999;17:2100–2104.PubMed
20.
Adida C, Berrebi D, Peuchmaur M, et al. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet. 1998;351:882–883.CrossRefPubMed
21.
Adida C, Haioun C, Gaulard P, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood. 2000;96:1921–1925.PubMed
22.
Kawasaki H, Altieri DC, Lu CD, et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998;58:5071–5074.PubMed
23.
Ambrosini G, Adida C, Sirugo G, Altieri DC. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem. 1998;273:11177–11182.CrossRefPubMed
24.
25.
Kouvidou Ch, Stefanaki K, Dai Y, et al. P21/waf1 protein expression in nasopharyngeal carcinoma. Comparative study with PCNA, p53 and mdm-2 protein expression. Anticancer Res. 1997;17:2615–2620.PubMed
26.
Sinicrope FA, Ruan SB, Cleary KR, et al. Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 1995;55:237–241.PubMed
27.
Rudin CD, Thompson CB. Apoptosis and disease: regulation and clinical relevance of programmed cell death. Annu Rev Med. 1997;48:267–281.CrossRefPubMed
28.
Takashima H, Nakajima T, Moriguchi M, et al. In vivo expression patterns of survivin and its splicing variants in chronic liver disease and hepatocellular carcinoma. Liver Int. 2005;25:77–84.CrossRefPubMed
29.
Zhang T, Otevrel T, Gao Z, et al. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res. 2001;61:8664–8667.PubMed
30.
Kim PJ, Plescia J, Clevers H, et al. Survivin and molecular pathogenesis of colorectal cancer. Lancet. 2003;362:205–209.CrossRefPubMed
31.
32.
Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456–1462.CrossRefPubMed
33.
Sakoguchi-Okada N, Takahashi-Yanaga F, Fukada K, et al. Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells. Biochem Pharmacol. 2007;73:1318–1329.CrossRefPubMed
34.
Suga K, Yamamoto T, Yamada Y, et al. Correlation between transcriptional expression of survivin isoforms and clinicopathological findings in human colorectal carcinomas. Oncol Rep. 2005;13:891–897.PubMed
35.
Okada E, Murai Y, Matsui K, et al. Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer Lett. 2001;163:109–116.CrossRefPubMed
36.
Rodriguez JA, Span SW, Ferreira CGM, et al. CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein survivin. Exp Cell Res. 2002;275:44–53.CrossRefPubMed
37.
Endo T, Abe S, Seidlar HB, et al. Expression of IAP family proteins in colon cancers from patients with different age groups. Cancer Immunol Immunother. 2004;53:770–776.CrossRefPubMed
38.
Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer. 2005;92:212–216.PubMed
39.
Gianani R, Jarboe E, Orlicky D, et al. Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol. 2001;32:119–125.CrossRefPubMed
40.
Krieg A, Mahotka C, Krieg T, et al. Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br J Cancer. 2002;86:737–743.CrossRefPubMed
41.
Lo Muzio L, Pannone G, Leonardi R, et al. Survivin, a potential early predictor of tumour progression in the oral mucosa. J Dent Res. 2003;82:923–928.CrossRefPubMed
42.
Zhang SQ, Qiang SY, Yiang JT, et al. Expression of survivin in different stages of carcinogenesis and progression of breast cancer. Ai Zheng. 2004;23:697–700.PubMed
43.
Grossman D, McNiff JM, Li F. Expression of apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Lab Invest. 1999;79:1121–1126.PubMed
44.
Lin LJ, Zheng CQ, Jin Y, et al. Expression of survivin protein in human colorectal carcinogenesis. World J Gastroenterol. 2003;9:974–977.PubMed
45.
Satoh K, Kaneko K, Hirota M, et al. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer. 2001;92:271–278.CrossRefPubMed
46.
Tanaka K, Iwamoto S, Gon G, et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 2000;6:127–134.PubMed
47.
Kennedy SM, O’Driscoll L, Purcell R, et al. Prognostic importance of survivin in breast cancer. Br J Cancer. 2003;88:1077–1083.CrossRefPubMed
48.
Lehner R, Lucia MS, Jarboe EA, et al. Immunohistochemical localization of the IAP protein survivin in bladder mucosa and transitional cell carcinoma. Appl Immunohistochem Mol Morphol. 2002;10:134–138.CrossRefPubMed
49.
Trieb K, Lehner R, Stulning T, et al. Survivin expression in human osteosarcoma is a marker for survival. Eur J Surg Oncol. 2003;29:379–382.CrossRefPubMed
50.
Lee YY, Yu CP, Lin CK, et al. Expression of survivin and cortactin in colorectal adenocarcinoma: association with clinicopathological parameters. Dis Markers. 2009;26(1):9–18.PubMed
51.
Junhe L, Wenjing H, Youjian H. The prediction of recurrence and survival of patients with Dukes’ B colorectal cancer after curative resection with immunohistochemical detection of Survivin and Livin expressions. Chin-Ger J Clin Oncol. 2008;7(1):P22–P26.CrossRef
Metadata
Title
Survivin Expression in Colorectal Carcinomas: Correlations with Clinicopathological Parameters and Survival
Authors
J. G. Kalliakmanis
Ch. Kouvidou
C. Latoufis
G. Kouvatseas
D. Anagnostakis
G. Papatheodoridis
J. Koskinas
A. Archimandritis
Publication date
01-10-2010
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 10/2010
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-009-1088-6

Other articles of this Issue 10/2010

Digestive Diseases and Sciences 10/2010 Go to the issue

Original Article

Incidence, Prevalence, Etiology, and Prognosis of First-Time Chronic Pancreatitis in Young Patients: A Nationwide Cohort Study

Original Article

Reconstitution of Secreted Frizzled-Related Protein 1 Suppresses Tumor Growth and Lung Metastasis in an Orthotopic Model of Hepatocellular Carcinoma

Original Article

Reduced Brain Content of Arachidonic Acid and Docosahexaenoic Acid Is Related to the Severity of Liver Fibrosis

Original Article

Role of Helicobacter pylori Infection in Gastroduodenal Damage in Patients Starting NSAID Therapy: 4 Months Follow-Up Study

Original Article

Acid-Related Upper Endoscopy Findings in Patients with Diabetes Versus Non-diabetic Patients

Case Report

The Man Who Swallowed a Table Knife: A Case Report
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits